0001209191-18-046706.txt : 20180815 0001209191-18-046706.hdr.sgml : 20180815 20180815074611 ACCESSION NUMBER: 0001209191-18-046706 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180813 FILED AS OF DATE: 20180815 DATE AS OF CHANGE: 20180815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goldman Steven M. CENTRAL INDEX KEY: 0001568216 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 181019745 MAIL ADDRESS: STREET 1: C/O DOVA PHARMACEUTICALS, INC. STREET 2: 240 LEIGH FARM ROAD, SUITE 245 CITY: DURHAM STATE: NC ZIP: 27707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2530 MERIDIAN PARKWAY STREET 2: SUITE 300 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 2530 MERIDIAN PARKWAY STREET 2: SUITE 300 CITY: DURHAM STATE: NC ZIP: 27713 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-08-13 0 0001685071 Dova Pharmaceuticals, Inc. DOVA 0001568216 Goldman Steven M. C/O DOVA PHARMACEUTICALS, INC. 240 LEIGH FARM ROAD, SUITE 245 DURHAM NC 27707 1 0 0 0 Common Stock 2018-08-13 4 M 0 1832 7.32 A 125001 D Common Stock 5000 I By LLC Stock Option (Right to Buy) 7.32 2018-08-13 4 M 0 1832 0.00 D 2027-05-24 Common Stock 1832 20168 D These shares are held by the Steven M. Goldman Family LLC (the "LLC"), of which the Reporting Person is the Managing Member. The voting and investment decisions of the LLC are made by an independent external asset manager. The Reporting Person disclaims beneficial ownership of the shares held by the LLC except to the extent of his pecuniary interest in the LLC, if any, and the inclusion of these shares on this report shall not be deemed an admission that the Reporting Person beneficially owns the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or any other purpose. The option vests over a period of three years as follows: (i) one-third of the total shares subject to the option shall vested on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service with the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock. /s/ Darren DeStefano, Attorney-in-Fact 2018-08-15